Metastatic breast cancer patient perceptions of somatic tumor genomic testing.

From pre-test (study entry) to post-test (end of study), there was no significant change in CES-D score (Wilcoxon p -value = 0.13), BAI score (Wilcoxon p -value = 0.50), TPS score (Wilcoxon p-value = 0.15), while CASE-cancer score decreased from pre- to post-test, marginally non-significant (Wilcoxon p-value = 0.05) (Fig. 2 a).

also in 1,493 other papers